Messenger RNA (mRNA) News and Research

RSS

Could mRNA vaccines triumph over other viral infections in humans and domestic animals?

Researchers review potential areas for mRNA vaccine development against pathogenic viruses other than SARS-CoV-2.

28 Nov 2022

A combined influenza and COVID-19 mRNA vaccine

A combined mRNA vaccine is capable of inducing broad and durable protection against co-infection with SARS-CoV-2 and IAV,

3 Aug 2022

Potential mRNA vaccines for influenza

Scientists discuss the benefits of shifting the global influenza vaccination system to a mRNA-based platform,

19 Jul 2022

Combating COVID cytokine storm with targeted nucleic acid therapies

Researchers examine current nucleic acid-based treatments against COVID-19 and their methods of action.

6 Mar 2022

Recycling tubular endosomes are associated with effective delivery of mRNA-based therapeutics, study finds

A recent study recently demonstrates the endosomal transport of nanoparticle-based formulations for the effective delivery of mRNA-based therapeutics.

14 Dec 2021

Study explores the effects of SARS-CoV-2 (and other betacoronaviruses) on cellular mRNA processing

A new study has been released on the bioRxiv* preprint server, which deals with a comprehensive survey on alternative splicing concerning SARS-CoV-2 infection. This study has also included two other betacoronavirurses (SARS-CoV and MERS), a control set of unrelated viruses, and a bacterium, namely, Streptococcus pneumonia. The study findings suggest that several cellular parameters are affected owing to a betacoronavirus infection, which in turn affects some genes and invariably various biological functions.

6 Jul 2021

Scientists identify breakthrough cases of SARS-CoV-2’s delta variant in fully vaccinated individuals

In a recent study conducted at the Baylor College of Medicine, Houston, USA, scientists have identified six vaccine breakthrough cases caused by the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Jul 2021

Can age, sex, BMI or blood group influence the immunogenicity of the Pfizer/BioNTech COVID-19 vaccine?

A group of Belgium researchers recently discuss their findings in the journal Microorganisms, which describe the influence of several factors on vaccine-induced immunogenicity.

1 Jul 2021

More evidence that mixing COVID-19 vaccines may help elicit a robust immune response

Eight volunteers who received a complete dose or a single dose of an mRNA vaccine or the ChAdOx1 vaccine after a dose of a trial gorilla adenovirus vaccine showed a significantly high level of antibodies and T cell response against SARS-CoV-2.

29 Jun 2021

Do the Moderna and Pfizer COVID-19 vaccines elicit different antibody responses?

A recent study led by scientists from the United States has compared the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response among clinicians who have been immunized with Pfizer/BioNTech or Moderna coronavirus disease 2019 (COVID-19) vaccine.

22 Jun 2021

Single BioNTech/Pfizer vaccine dose reduces risk of COVID-19 by nearly 52%, matching clinical trial data

Data gathered from real-world vaccination programs following a single dose of Pfizer vaccine administration shows a reduction of 51.4% in infection risk and effectiveness of 54.4% against symptomatic coronavirus disease 2019 (COVID-19), matching clinical trial results.

7 Jun 2021

Pfizer-BioNTech vaccination not associated with platelet activation in new study

Among the devastating complications of severe or critical coronavirus disease 2019 (COVID-19), clot formation ranks high in the adverse impact it creates. An important question is whether SARS-CoV-2-spike-based vaccines also cause such coagulopathies. A new study, released as a preprint on the medRxiv* server, examines this risk for the first time.

21 May 2021

No placental damage observed in case study of pregnant women with mRNA COVID-19 vaccinations

New research by a team at Northwestern University Feinberg School of Medicine, USA, suggests that the COVID-19 vaccine does not damage the placenta and may be safe to use during pregnancy.

13 May 2021

mRNA-based COVID-19 vaccines are effective against Indian SARS-CoV-2 variant, says study

A team of scientists recently conducted a study to examine whether natural infection-induced or vaccine-induced neutralizing antibodies are capable of eliminating the risk of recently emerged Indian variant (B.1.617.1) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

12 May 2021

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Researchers in The Netherlands have warned that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces complex reprogramming of innate immune responses that should be considered in the development and use of mRNA-based vaccines.

10 May 2021

Moderna COVID-19 vaccine makes it on WHO Emergency Use Listing

Moderna has announced Emergency Use Listing granted by the World Health Organization for its COVID-19 mRNA vaccine.

4 May 2021

Study examines mRNA COVID-19 vaccine’s effectiveness across age and gender

The findings reveal that although the two-dose vaccine regimen initially induces robust antibody response in all age groups, older male individuals are particularly associated with a gradual decline in vaccine-induced immunity six weeks after the second vaccine dose.

28 Apr 2021

Previous SARS-CoV-2 infection associated with more adverse events following mRNA vaccination

The phase 3 trials of the Pfizer and Moderna COVID-19 vaccines did not include those with a known previous SARS-CoV-2 infection. Recent evidence indicates that mRNA vaccines may induce more adverse events in these individuals. In a recent study, 947 individuals, 265 of which have previously reported SARS-CoV-2 infection, were monitored post-vaccination for adverse events, finding that there could be a link between previous infection and greater incidence of these events.

26 Apr 2021

Researchers study host and viral transcriptomes in tandem to shed light on SARS-CoV-2 infection

In a new study, researchers discuss the use of simultaneous sequencing of both human and viral genes to better understand SARS-CoV-2's infection pathway.

15 Feb 2021

Pfizer/BioNTech COVID-19 vaccine elicits both neutralizing antibodies and T cell response

A new study published on the preprint server medRxiv by a research group from the U.S. and Germany indicates that a novel BNT162b1 RNA-based vaccine against coronavirus disease (COVID-19) induces functional and proinflammatory T cell responses in almost all participants – marking another landmark achievement for this promising vaccine candidate.

21 Jul 2020